{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:34:07Z","timestamp":1786988047649,"version":"build-2736575974"},"reference-count":105,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.ejim.2014.03.001","type":"journal-article","created":{"date-parts":[[2014,3,23]],"date-time":"2014-03-23T07:49:45Z","timestamp":1395560985000},"page":"430-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Multimodal treatment of hepatocellular carcinoma"],"prefix":"10.1016","volume":"25","author":[{"given":"Dirk","family":"Graf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Vallb\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram Trudo","family":"Knoefel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patric","family":"Kr\u00f6pil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Antoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahaman","family":"Sagir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"H\u00e4ussinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2014.03.001_bb0005","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","article-title":"Primary liver cancer: worldwide incidence and trends","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejim.2014.03.001_bb0015","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL\u2013EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0020","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0025","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma. An update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-2007-1007122","article-title":"Prognosis of hepatocellular carcinoma: the BCLC staging classification","volume":"19","author":"Llovet","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2014.03.001_bb0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/13651820410024058","article-title":"Staging systems in hepatocellular carcinoma","volume":"7","author":"Pons","year":"2005","journal-title":"HPB"},{"key":"10.1016\/j.ejim.2014.03.001_bb0040","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1001\/jama.2013.6629","article-title":"Personalized medicine vs guideline-based medicine","volume":"309","author":"Goldberger","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2014.03.001_bb0045","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep.25832","article-title":"Resection of hepatocellular cancer \u22642cm: results from two Western centers","volume":"57","author":"Roayaie","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0050","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.21933","article-title":"Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice?","volume":"47","author":"Livraghi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0055","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1600-6143.2011.03853.x","article-title":"Are patients with Child's A cirrhosis and hepatocellular carcinoma appropriate candidates for liver transplantation?","volume":"12","author":"Berry","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ejim.2014.03.001_bb0060","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1053\/jhep.2000.20456","article-title":"Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan","volume":"32","author":"Arii","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0065","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jhep.2008.01.022","article-title":"Novel advancements in the management of hepatocellular carcinoma in 2008","volume":"48","author":"Llovet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0070","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hep.23485","article-title":"A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma","volume":"51","author":"Cabibbo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0075","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival","volume":"38","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0080","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/annonc\/mdt054","article-title":"Intermediate hepatocellular carcinoma: current treatments and future perspectives","volume":"24","author":"Dufour","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.gastro.2006.05.021","article-title":"Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. The Liver Cancer Study Group of Japan","volume":"131","author":"Takayasu","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0090","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jhep.2012.01.008","article-title":"Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. Implications for clinical practice and trial design","volume":"56","author":"Burrel","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0095","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1002\/hep.22506","article-title":"Molecular targeted therapies in hepatocellular carcinoma","volume":"48","author":"Llovet","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0100","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.03.001_bb0105","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1440-1746.2011.06917.x","article-title":"Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases","volume":"27","author":"Jung","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(11)70144-9","article-title":"Italian Liver Cancer Group. Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study","volume":"12","author":"Vitale","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0115","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1053\/jhep.2000.9033","article-title":"Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases","volume":"32","author":"Bralet","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00268-007-9291-0","article-title":"Long-term outcome of liver resection for hepatocellular carcinoma in noncirrhotic nonfibrotic liver with no viral hepatitis or alcohol abuse","volume":"32","author":"Lubrano","year":"2008","journal-title":"World J Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0125","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1072-7515(02)01163-8","article-title":"Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10cm in diameter","volume":"194","author":"Poon","year":"2002","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0130","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1245\/ASO.2003.03.072","article-title":"Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10cm: two decades of experience at Chang Gung Memorial Hospital","volume":"10","author":"Yeh","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0135","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/01.SLA.0000065265.16728.C0","article-title":"Preoperative portal vein embolization for extended hepatectomy","volume":"237","author":"Hemming","year":"2003","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0140","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.sla.0000201482.11876.14","article-title":"Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up","volume":"243","author":"Nagino","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0145","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/bjs.8955","article-title":"In situ liver transection with portal vein ligation for rapid growth of the future liver remnant in two-stage liver resection","volume":"100","author":"Knoefel","year":"2013","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0150","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/SLA.0b013e31824856f5","article-title":"Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings","volume":"255","author":"Schnitzbauer","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0155","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jamcollsurg.2007.03.002","article-title":"Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers","volume":"205","author":"Lang","year":"2007","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0160","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/bjs.7401","article-title":"Resection of hepatocellular carcinoma in patients without cirrhosis","volume":"98","author":"Smoot","year":"2011","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0165","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00423-012-0911-2","article-title":"HCC: current surgical treatment concepts","volume":"397","author":"Cauchy","year":"2012","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0170","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/cncr.20426","article-title":"Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey","volume":"101","author":"Ikai","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejim.2014.03.001_bb0175","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/liv.12199","article-title":"Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients","volume":"33","author":"Giannini","year":"2013","journal-title":"Liver Int"},{"key":"10.1016\/j.ejim.2014.03.001_bb0180","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000000236","article-title":"Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma","author":"Zhong","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(89)92101-6","article-title":"Liver transplantation from live donors","volume":"26","author":"Raia","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2014.03.001_bb0190","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.03.001_bb0200","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/BF01659064","article-title":"Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients","volume":"15","author":"Ringe","year":"1991","journal-title":"World J Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0205","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/lt.21999","article-title":"Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States","volume":"16","author":"Pomfret","year":"2010","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ejim.2014.03.001_bb0210","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/SLA.0b013e318148c704","article-title":"Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA","volume":"246","author":"Duffy","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0215","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/hep.24231","article-title":"Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation","volume":"53","author":"Bhangui","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0220","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/lt.20311","article-title":"Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study","volume":"10","author":"Leung","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ejim.2014.03.001_bb0225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000106911","article-title":"HCC in living donor liver transplantation: can we expand the Milan criteria?","volume":"25","author":"Kwon","year":"2007","journal-title":"Dig Dis"},{"key":"10.1016\/j.ejim.2014.03.001_bb0230","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/lt.21940","article-title":"Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival","volume":"15","author":"Vakili","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ejim.2014.03.001_bb0235","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13244-010-0027-6","article-title":"Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: what is the evidence today","volume":"3","author":"Seinstra","year":"2010","journal-title":"Insights Imag"},{"key":"10.1016\/j.ejim.2014.03.001_bb0240","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.23725","article-title":"Loco-regional treatment of hepatocellular carcinoma","volume":"52","author":"Lencioni","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0245","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1148\/radiol.11110144","article-title":"Local-regional treatment of hepatocellular carcinoma","volume":"262","author":"Lencioni","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0250","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1080\/00365520701885481","article-title":"Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial","volume":"43","author":"Brunello","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0255","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1148\/radiol.2281020718","article-title":"Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection","volume":"228","author":"Lencioni","year":"2003","journal-title":"Radiology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0260","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1053\/j.gastro.2004.09.003","article-title":"Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4cm","volume":"127","author":"Lin","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0265","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/gut.2004.045203","article-title":"Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3cm or less","volume":"54","author":"Lin","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.ejim.2014.03.001_bb0270","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1053\/j.gastro.2005.04.009","article-title":"A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma","volume":"129","author":"Shiina","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0275","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","article-title":"A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma","volume":"243","author":"Chen","year":"2006","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0280","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","article-title":"A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria","volume":"252","author":"Huang","year":"2010","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0285","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","article-title":"A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma","volume":"57","author":"Feng","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0290","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.3748\/wjg.v19.i26.4106","article-title":"Systematic review of surgical resection vs radiofrequency ablation for hepatocellular carcinoma","volume":"19","author":"Cucchetti","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0295","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1477-7819-11-190","article-title":"Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis","volume":"11","author":"Duan","year":"2013","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0300","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000342813","article-title":"Multimodality treatment for early-stage hepatocellular carcinoma: a bridging therapy for liver transplantation","volume":"86","author":"Ashoori","year":"2012","journal-title":"Digestion"},{"key":"10.1016\/j.ejim.2014.03.001_bb0305","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/hep.20688","article-title":"Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation","volume":"41","author":"Lu","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0310","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1245\/ASO.2004.02.026","article-title":"Extracorporeal high intensity focused ultrasound ablation in the treatment of patients with large hepatocellular carcinoma","volume":"11","author":"Wu","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0315","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/j.ejca.2010.06.015","article-title":"Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma","volume":"46","author":"Li","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejim.2014.03.001_bb0320","doi-asserted-by":"crossref","first-page":"e68453","DOI":"10.1371\/journal.pone.0068453","article-title":"Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis","volume":"8","author":"Liao","year":"2013","journal-title":"PLOS One"},{"key":"10.1016\/j.ejim.2014.03.001_bb0325","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/SLA.0b013e3182822c02","article-title":"Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma","volume":"257","author":"Chan","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejim.2014.03.001_bb0330","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1200\/JCO.2008.19.0082","article-title":"Long-term outcome of cirrhotic patients with early hepatocellular carcinoma treated with ultrasound-guided percutaneous laser ablation: a retrospective analysis","volume":"27","author":"Pacella","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0335","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1148\/radiol.2463070390","article-title":"Complications of laser ablation for hepatocellular carcinoma: a multicenter study","volume":"246","author":"Arienti","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0340","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1148\/radiol.2351031944","article-title":"Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation","volume":"235","author":"Liang","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0345","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.crad.2012.05.007","article-title":"Percutaneous microwave ablation of larger hepatocellular carcinoma","volume":"68","author":"Liu","year":"2013","journal-title":"Clin Radiol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0350","first-page":"1599","article-title":"Radiotherapy and hepatocellular carcinoma: update and review of literature","volume":"16","author":"Ursino","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ejim.2014.03.001_bb0355","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","article-title":"Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma","volume":"31","author":"Bujold","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0360","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/jgh.12087","article-title":"Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma","volume":"28","author":"Honda","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0365","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/jgh.12087","article-title":"Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma","volume":"28","author":"Takeda","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0370","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/lt.23439","article-title":"Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation","volume":"18","author":"O'Connor","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.ejim.2014.03.001_bb0375","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1593\/tlo.12448","article-title":"Stereotactic body radiation therapy for primary and metastatic liver tumors","volume":"6","author":"Liu","year":"2013","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0380","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiol.2241011262","article-title":"Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials","volume":"224","author":"Camm\u00e0","year":"2002","journal-title":"Radiology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0385","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0016-5085(88)90436-2","article-title":"Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma\u2014a randomized controlled trial","volume":"94","author":"Lin","year":"1988","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0390","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1056\/NEJM199505113321903","article-title":"Group d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome H\u00e9patocellulaire","volume":"332","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2014.03.001_bb0395","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(98)80187-6","article-title":"Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC","volume":"29","author":"Pelletier","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0400","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/hep.510270617","article-title":"Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution","volume":"27","author":"Bruix","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0405","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2014.03.001_bb0410","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0415","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00117-011-2211-1","article-title":"Transarterial ablation of hepatocellular carcinoma. Status and developments","volume":"52","author":"Radeleff","year":"2012","journal-title":"Radiologe"},{"key":"10.1016\/j.ejim.2014.03.001_bb0420","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0425","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.jhep.2011.09.012","article-title":"Liver\/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads","volume":"56","author":"Guiu","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0430","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00270-009-9752-y","article-title":"Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up","volume":"33","author":"Bonomo","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0435","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00270-009-9750-0","article-title":"Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma","volume":"33","author":"Malagari","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0440","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.clcc.2011.11.003","article-title":"Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma","volume":"11","author":"Morse","year":"2012","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ejim.2014.03.001_bb0445","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ctrv.2010.07.006","article-title":"Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization","volume":"37","author":"Raoul","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejim.2014.03.001_bb0450","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1055\/s-0029-1245380","article-title":"Selective internal radiotherapy (SIRT) for hepatocellular carcinoma","volume":"182","author":"Antoch","year":"2010","journal-title":"Rofo"},{"key":"10.1016\/j.ejim.2014.03.001_bb0455","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","article-title":"Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma","volume":"140","author":"Salem","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0460","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/hep.24451","article-title":"Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation","volume":"54","author":"Sangro","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0465","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival","volume":"52","author":"Hilgard","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2014.03.001_bb0470","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijrobp.2006.11.060","article-title":"Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium","volume":"68","author":"Kennedy","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejim.2014.03.001_bb0475","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0480","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1742-1241.2012.02940.x","article-title":"First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study","volume":"66","author":"Lencioni","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2014.03.001_bb0485","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1365-2036.2011.04860.x","article-title":"Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child\u2013Pugh score","volume":"34","author":"Hollebecque","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.ejim.2014.03.001_bb0490","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00280-011-1616-x","article-title":"Sorafenib for hepatocellular carcinoma according to Child\u2013Pugh class of liver function","volume":"68","author":"Kim","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0495","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jhep.2012.01.006","article-title":"Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma","volume":"56","author":"Park","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0500","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/ijc.27925","article-title":"Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial","volume":"132","author":"Chung","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejim.2014.03.001_bb0505","doi-asserted-by":"crossref","first-page":"364","DOI":"10.4254\/wjh.v5.i7.364","article-title":"Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma","volume":"5","author":"Muhammad","year":"2013","journal-title":"World J Hepatol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0510","series-title":"Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial","first-page":"LBA154","author":"Lencioni","year":"2012"},{"key":"10.1016\/j.ejim.2014.03.001_bb0515","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1055\/s-0033-1333632","article-title":"Emerging targeted strategies in advanced hepatocellular carcinoma","volume":"33","author":"Finn","year":"2013","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.ejim.2014.03.001_bb0520","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11912-012-0233-0","article-title":"Management of hepatocellular carcinoma: beyond sorafenib","volume":"14","author":"Chan","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejim.2014.03.001_bb0525","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/CCO.0b013e3283621074","article-title":"Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding?","volume":"25","author":"Dekervel","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejim.2014.03.001_bb0530","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1470-2045(12)70490-4","article-title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","volume":"14","author":"Santoro","year":"2013","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620514000764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620514000764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T16:53:21Z","timestamp":1648659201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620514000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0953620514000764"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2014.03.001","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multimodal treatment of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2014.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}